Applied Molecular Transport to Present at BofA Securities 2022 Healthcare Conference
05/05/2022 - 04:01 PM
SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the BofA Securities 2022 Healthcare Conference in Las Vegas on Tuesday, May 10, 2022 at 2:20 p.m. ET (11:20 a.m. PT).
A live webcast will be accessible via the Events page of the Applied Molecular Transport website at https://ir.appliedmt.com/news-events/events . An archived replay will be available for 30 days following the event.
About Applied Molecular Transport Inc.
AMT is a clinical-stage biopharmaceutical company developing novel oral biologic product candidates, by leveraging its technology platform to design and advance a multi-product pipeline to treat autoimmune, inflammatory, metabolic and other diseases. AMT is developing its oral biologic product candidates in patient-friendly oral dosage forms that are designed to either target local intestinal tissue or enter systemic circulation to precisely address the relevant pathophysiology of disease. AMT’s proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of diverse therapeutic modalities across the IE barrier. Active transport is an efficient mechanism that uses the cell’s own machinery to transport materials across the IE barrier.
AMT’s headquarters, internal GMP manufacturing and lab facilities are located in South San Francisco, CA. For additional information on AMT, please visit www.appliedmt.com .
Investor Relations Contact: achang@appliedmt.com
Media Contacts: asantos@wheelhouselsa.com
Aljanae Reynolds
Applied Molecular Transport Inc
AMTI Rankings
N/A Ranked by Stock Gains
AMTI Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
About AMTI
applied molecular transport is developing a pipeline of transformative, targeted oral biological therapeutics that promise to redefine the future of biopharmaceuticals. our deep scientific foundations in mucosal immunology and microbiome-epithelial interfaces have led to the development of powerful technology platforms that are fueling a unique pipeline of first-in-class molecules to treat a wide range of grievous diseases. our oral biopharmaceutical products mimic the biology of microbial and other natural processes that modulate health and disease via mucosal immunology pathways. our targeted therapeutics are directed to the right location to intercept disease at the point of origin of dysregulation. we are advancing a pipeline of targeted oral biological therapeutics to treat autoimmune, inflammation and other diseases, including those associated with cancer, metabolic and hepatologic disorders. our overriding patient-centric goal is to open new biological possibilities based on nov
